Beyond the ANDA: How the 505(b)(2) Pathway Can Turn “Generic” Competition Into Differentiated Advantage
Most pharma leaders treat the 505(b)(2) pathway as a tactical workaround—something you use when the full story of a drug isn’t captured in an ANDA-r…

Pharma IP teams are used to thinking in timelines: filing dates, priority claims, prosecution milestones, and—eventually—patent expiry.
But right now, the timeline that matters most may be the one you can’t ignore: Russia’s patent term extensions.
If y…

Litigation-Aware Prosecution: Turn Your Drug Patent Portfolio Into a Competitive Assertion Asset
Most drug patent portfolios are built like insurance policies—file early, hope for broad coverage, and assume the courtroom will sort out the details.
But …

Hospitals don’t lose money because they can’t negotiate. They lose money because they don’t see the clock.
That’s the uncomfortable takeaway from the latest discussion on patent expiration intelligence—and why the GPO contract “weapon” many hospitals r…

Generic launches don’t “just happen.” They’re engineered by timelines.
If you’re still forecasting generic drug launch dates using spreadsheets, historical averages, or gut feel, you’re already behind. In branded pharma, timing is strategy. In generi…

Most people “read” the FDA Orange Book. The best people mine it.
If you’re in pharma BD, licensing, investing, or competitive intelligence, you already know the Orange Book is more than a regulatory directory—it’s a map of where IP value is likely to b…

Biotech investors love to talk about “pipeline value.” But most portfolio rankings still start with a gut check: which asset is most exciting, which company has the best story, which trial looks cleanest on slide decks.
That’s not a strategy. It’s a vi…

Biopharma is entering a talent cliff—and it’s happening before most teams even realize they’re standing at the edge.
The “patent cliff” is usually discussed in terms of revenue: blockbuster drugs lose exclusivity, generics rush in, and forecasts get re…

Stop Overstocking Branded Drugs: Patent Intelligence Is the New Risk Control for Wholesalers
Branded drug inventory risk isn’t just a balance-sheet problem—it’s a timing problem.
When wholesalers overstock branded products, the pain usually arrives all…

Big Pharma’s “patent cliff” isn’t just a revenue story—it’s a workforce story.
When blockbuster exclusivity ends, the market doesn’t simply swap one drug for another. It forces a rapid reallocation of capital, attention, and headcount across R&D, c…